Ovid Therapeutics Reports Q4 2025 Results

Ovid Therapeutics Reports Q4 2025 Results
Ovid Therapeutics Inc. released its fourth quarter 2025 earnings presentation, providing investors with a comprehensive overview of the company's financial performance and operational progress throughout the year. The biopharmaceutical company, trading under the ticker NASDAQ:OVID, shared detailed insights into its clinical development programs and business strategy moving forward into 2026. The earnings call presentation highlighted key metrics across the company's pipeline, including updates on rare disease programs that represent the core focus of Ovid's research and development efforts. As a specialized pharmaceutical company concentrating on neurological and genetic disorders, Ovid continues to advance multiple candidates through various stages of clinical trials.